A Phase 4 interventional study of bimatoprost ophthalmic solution 0.01% and travoprost ophthalmic solution 0.004% in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-07.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 18th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2010, is one of 22 in phase 4, and was the 25th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
58 studies in Glaucoma, Open-Angle by AbbVie: 1 open now, 3 under way, 1 of them phase 3. Of 54 finished, 42 (78%) have results posted.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 17th largest by enrollment of the 34 interventional ones that give a count, is one of 12 that started in 2010, is one of 14 in phase 4, and was the 17th registered.
AbbVie’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 58 in Glaucoma, Open-Angle:
This tab as a report to print or save as PDF → With an account.
This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma or ocular hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks.
Drug: bimatoprost ophthalmic solution 0.01%
One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks.
Drug: travoprost ophthalmic solution 0.004%
One drop of latanoprost ophthalmic solution 0.005% (Xalatan®) administered to affected eye(s), once daily in the evening for 12 weeks.
Drug: latanoprost ophthalmic solution 0.005%
One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
Also known as: Lumigan® 0.01%, Lumigan® RC
One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
Also known as: Travatan Z®
One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
Also known as: Xalatan®
Mean Conjunctival Hyperemia at Week 12
Conjunctival hyperemia was analyzed using the average of the scores of both eyes. Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia was graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness).
Time frame: Week 12
Mean Corneal Staining With Fluorescein at Week 12
Corneal staining was analyzed using the average of the scores of both eyes. The cornea is the transparent front part of the eye which covers the iris and pupil. To detect the presence or absence of corneal puncta (tiny disruptions in the surface of the eye), fluorescein dye is administered into the eye and the eye is graded using a 5-point scale where 0=None (no puncta), 0.5=Trace (1-5 puncta), 1=Mild (6-20 puncta), 2=Moderate (\>20 puncta) and 3=Severe (too many puncta to count).
Time frame: Week 12
Mean Tear Break Up Time (TBUT) at Week 12
Tear Break Up Time was analyzed using the average of the readings of both eyes. TBUT is defined as the time (seconds) required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film.
Time frame: Week 12
| Milestone | Bimatoprost Ophthalmic Solution 0.01% | Travoprost Ophthalmic Solution 0.004% | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|---|
| Started | 56 | 53 | 55 |
| Completed | 51 | 51 | 51 |
| Not completed | 5 | 2 | 4 |
Conjunctival hyperemia was analyzed using the average of the scores of both eyes. Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia was graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness).
| Score on a scale | Bimatoprost Ophthalmic Solution 0.01% | Travoprost Ophthalmic Solution 0.004% | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|---|
| Mean Conjunctival Hyperemia at Week 12 | 0.42 ± 0.48 | 0.46 ± 0.44 | 0.44 ± 0.57 |
Corneal staining was analyzed using the average of the scores of both eyes. The cornea is the transparent front part of the eye which covers the iris and pupil. To detect the presence or absence of corneal puncta (tiny disruptions in the surface of the eye), fluorescein dye is administered into the eye and the eye is graded using a 5-point scale where 0=None (no puncta), 0.5=Trace (1-5 puncta), 1=Mild (6-20 puncta), 2=Moderate (\>20 puncta) and 3=Severe (too many puncta to count).
| Score on a scale | Bimatoprost Ophthalmic Solution 0.01% | Travoprost Ophthalmic Solution 0.004% | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|---|
| Mean Corneal Staining With Fluorescein at Week 12 | 0.31 ± 0.45 | 0.32 ± 0.48 | 0.22 ± 0.30 |
Tear Break Up Time was analyzed using the average of the readings of both eyes. TBUT is defined as the time (seconds) required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film.
| Seconds | Bimatoprost Ophthalmic Solution 0.01% | Travoprost Ophthalmic Solution 0.004% | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|---|
| Mean Tear Break Up Time (TBUT) at Week 12 | 9.7 ± 5.71 | 9.7 ± 4.96 | 9.3 ± 4.04 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bimatoprost Ophthalmic Solution 0.01% | — | 1/56 (1.8%) | 0/56 (0%) |
| Travoprost Ophthalmic Solution 0.004% | — | 1/53 (1.9%) | 0/53 (0%) |
| Latanoprost Ophthalmic Solution 0.005% | — | 3/55 (5.5%) | 0/55 (0%) |
| Event | Bimatoprost Ophthalmic Solution 0.01% | Travoprost Ophthalmic Solution 0.004% | Latanoprost Ophthalmic Solution 0.005% |
|---|---|---|---|
| Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/56 | 1/53 | 0/55 |
| Gastrointestinal BleedGastrointestinal disorders | 0/56 | 0/53 | 1/55 |
| Aspiration Pneumonia resulting in deathRespiratory, thoracic and mediastinal disorders | 0/56 | 0/53 | 1/55 |
| Punctured colonGastrointestinal disorders | 0/56 | 0/53 | 1/55 |
| Infection from Punctured colonInfections and infestations | 0/56 | 0/53 | 1/55 |
| Transient Ischemic AttackVascular disorders | 0/56 | 0/53 | 1/55 |
| Branch retinal artery occlusionEye disorders | 1/56 | 0/53 | 0/55 |
| Age Continuous(Years) | Bimatoprost Ophthalmic Solution 0.01% | Travoprost Ophthalmic Solution 0.004% | Latanoprost Ophthalmic Solution 0.005% | Total |
|---|---|---|---|---|
| Mean | 65.1 ± 11.76 | 63.2 ± 13.57 | 64.7 ± 12.28 | 64.3 ± 12.49 |
| Sex: Female, Male(Participants) | Bimatoprost Ophthalmic Solution 0.01% | Travoprost Ophthalmic Solution 0.004% | Latanoprost Ophthalmic Solution 0.005% | Total |
|---|---|---|---|---|
| Female | 36 | 25 | 31 | 92 |
| Male | 20 | 28 | 24 | 72 |
The record gives a start of Dec 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bimatoprost Ophthalmic Solution · Travoprost · Latanoprost